Clinical review report: Apomorphine hydrochloride (Kynmobi) (Sunovion Pharmaceuticals Canada Inc.) indication: the acute, intermittent treatment of "OFF" episodes in patients with Parkinson disease
The objective of the current CADTH Common Drug Review was to perform a systematic review of the beneficial and harmful effects of apomorphine hydrochloride sublingual film (Kynmobi) for the acute, intermittent treatment of OFF episodes in patients with Parkinson disease
Corporate Author: | |
---|---|
Format: | eBook |
Language: | English |
Published: |
Ottawa (ON)
Canadian Agency for Drugs and Technologies in Health
2021, April 2021
|
Edition: | Final (with redactions) |
Series: | CADTH common drug review
|
Online Access: | |
Collection: | National Center for Biotechnology Information - Collection details see MPG.ReNa |
Summary: | The objective of the current CADTH Common Drug Review was to perform a systematic review of the beneficial and harmful effects of apomorphine hydrochloride sublingual film (Kynmobi) for the acute, intermittent treatment of OFF episodes in patients with Parkinson disease |
---|---|
Physical Description: | 1 PDF file (99 pages) illustrations |